#USA #Northbrook #710GO #ObesityWeek #Kalohexis

Kalohexis' Groundbreaking Presentation at ObesityWeek 2026

Kalohexis, Inc., a pioneering clinical-stage biotechnology firm based in Northbrook, Illinois, is set to showcase its innovative research at the ObesityWeek 2026 Annual Meeting, scheduled for November 14-17, 2026, in Washington, D.C. This prominent event aims to present the latest advancements and treatments in obesity and metabolic conditions.

Melanocortin Agonism: A New Frontier in Obesity Treatment

At the core of Kalohexis' presentation is its groundbreaking oral melanocortin-3 receptor/melanocortin-4 receptor (MC3R/MC4R) dual agonist, 710GO. This novel compound aims to tackle general obesity more effectively and durably than existing treatments, leveraging the body's natural melanocortin system.

Key Presentation Details:

• - Session Title: Diabetes, Weight Management: Sex-Specific Outcomes
• - Presented by: Dr. Allison Gardner, Director of Communications at Kalohexis
• - Date and Time: Saturday, November 14, 2026, from 7:30 PM to 8:30 PM ET
• - Location: Gaylord National Resort Convention Center Exhibit Hall BCD

The poster titled, “Melanocortin Agonism Drives Lean-Mass-Sparing Weight Loss with Increased Energy Expenditure in Obese Mice and Enhances Semaglutide-Associated Weight Loss,” will highlight significant data demonstrating the efficacy of 710GO in driving weight loss while preserving lean body mass.

The Promise of 710GO

Currently, 710GO is undergoing Phase 1 clinical trials, where its potential as a healthier and more effective treatment for obesity is being evaluated. The dual action of this agonist could revolutionize treatment methodologies for individuals struggling with obesity by maximizing weight loss while maintaining essential muscle mass.

By harnessing the melanocortin system, which is crucial in regulating metabolic homeostasis, Kalohexis aims to reshape how metabolic disorders like obesity and cancer cachexia are approached. This strategy not only targets weight management but also emphasizes overall metabolic health.

About Kalohexis, Inc.

Kalohexis was founded in March 2026 as a spinoff from Endevica Bio. The company is on a mission to leverage the melanocortin system to foster innovative solutions for metabolic diseases. Kalohexis is currently developing a pipeline of peptide therapeutics designed to engage the MC3R and MC4R effectively. Their leading candidates include 710GO and mifomelatide, the latter aimed at treating cachexia in cancer patients. With a focus on safety and efficacy, Kalohexis strives to provide patients with transformative treatments to improve their quality of life.

For ongoing updates on Kalohexis, their research, and participation in future events, visit their official website kalohexis.com or connect with them on social media platforms such as LinkedIn and X.

As the ObesityWeek 2026 approaches, the spotlight will be on Kalohexis and its pioneering research that could pave the way for more effective obesity treatments. Their participation underscores an essential shift towards the scientific understanding and management of metabolic disorders, promising a healthier future for many.